Tanaka Kuniya, Shimada Hiroshi, Ueda Michio, Matsuo Kenichi, Endo Itaru, Togo Shinji
Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan.
Ann Surg Oncol. 2007 Apr;14(4):1336-46. doi: 10.1245/s10434-006-9071-3. Epub 2007 Jan 18.
We investigated factors affecting 5-year survival in patients undergoing hepatic resection for colorectal cancer metastases, including events long after initial hepatectomy. Although retrospective studies have demonstrated survival benefit of hepatectomy for metastatic colorectal cancer, few have included sufficient 5-year survivors to identify survival-related factors throughout the clinical course.
We divided 156 patients with hepatectomy for colorectal cancer metastases into 5-year survivors (n = 64) and patients dying before 5 years after hepatectomy (n = 92). Clinicopathologic data were compared retrospectively with respect to long-term outcome.
By multivariate analysis, large liver tumors (adjusted relative risk, 2.029; P = .011), short tumor doubling time (1.809; P = .026), and origin from poorly differentiated primary adenocarcinoma (12.632; P = .001) compromised survival, whereas initial treatment-related variables did not. Although no difference was seen in initial treatment-related variables between 5-year survivors with recurrence after hepatectomy and patients dying before 5 years, repeat surgery was used more frequently in survivors (P < .001), typically with adjuvant chemotherapy.
Reoperations for each recurrence of metastases, followed by additional chemotherapy, frequently resulted in long survival.
我们研究了影响接受结直肠癌肝转移灶切除患者5年生存率的因素,包括初次肝切除术后很长一段时间内的事件。尽管回顾性研究已证明肝切除对转移性结直肠癌有生存益处,但很少有研究纳入足够数量的5年生存者以确定整个临床过程中的生存相关因素。
我们将156例行结直肠癌肝转移灶切除的患者分为5年生存者(n = 64)和肝切除术后5年内死亡的患者(n = 92)。回顾性比较临床病理数据与长期预后的关系。
多因素分析显示,肝肿瘤体积大(校正相对风险,2.029;P = 0.011)、肿瘤倍增时间短(1.809;P = 0.026)以及原发于低分化腺癌(12.632;P = 0.001)会影响生存,而初始治疗相关变量则无此影响。尽管肝切除术后复发的5年生存者与5年内死亡的患者在初始治疗相关变量方面无差异,但生存者更频繁地接受再次手术(P < 0.001),通常还会接受辅助化疗。
对每次转移复发进行再次手术,随后进行额外化疗,常常可带来长期生存。